InvestorsHub Logo
Followers 37
Posts 4949
Boards Moderated 0
Alias Born 11/13/2010

Re: None

Sunday, 01/20/2019 12:07:42 PM

Sunday, January 20, 2019 12:07:42 PM

Post# of 1205
“We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research.”https://www.analystratings.com/articles/analysts-are-bullish-on-these-healthcare-stocks-agile-therapeutics-agrx-novabay-pharma-nby/
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.